<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7120554/results/search/test_trace/results.xml">
  <result pre="its later approval in 1963, a new era of antiviral" exact="treatment" post="development began (De Clercq and Li 2016). Because of"/>
  <result pre="a specific antiviral agent in the course of an acute" exact="infection" post="(Rollinson 1992a, b). Most of the antiviral drugs used"/>
  <result pre="human antiviral agents are being used with cascade principle for" exact="treatment" post="of animal diseases (e.g. acyclovir, idoxuridine and trifluridine against"/>
  <result pre="diseases (e.g. acyclovir, idoxuridine and trifluridine against feline herpesvirus-1 ocular" exact="infection" post="in cats) (Thiry et al. 2009). Currently, the only"/>
  <result pre="as neuraminidase (oseltamivir) or amino acid (L-lysine) inhibitors, while novel" exact="treatment" post="options such as small inhibitory RNAs are also under"/>
  <result pre="medicine with the development of novel and sophisticated diagnostic and" exact="treatment" post="protocols. In addition to that, current measures for control"/>
  <result pre="limitations. Therefore, antiviral agents represent a promising alternative for the" exact="treatment" post="of viral diseases in veterinary medicine (Dal Pozzo and"/>
  <result pre="example of this approach is azidothymidine (AZT), used in the" exact="treatment" post="of human immunodeficiency virus (HIV), which acts by inhibiting"/>
  <result pre="well (Olivero 2018). The other widely used approach is high-throughput" exact="screening" post="(HTS) methods, which enable validation of a number of"/>
  <result pre="and RNAi screens (Szymański et al. 2012). Targeted or selected" exact="screening" post="is based on identification of compounds that can selectively"/>
  <result pre="poxviruses, arenaviruses, etc. (Marriott et al. 1999). Another commonly used" exact="screening" post="method is diversity screening, based on identification of compounds"/>
  <result pre="involves a much broader target base, instead of focusing the" exact="screening" post="against one specific protein of interest. It has been"/>
  <result pre="virus and New World arenaviruses (Valler and Green 2000). High-content" exact="screening" post="(HCS) is a subclass of diversity screening method developed"/>
  <result pre="Green 2000). High-content screening (HCS) is a subclass of diversity" exact="screening" post="method developed upon automation of cellular imaging and analysis"/>
  <result pre="of virus-positive cells (Brodin and Christophe 2011). Another type of" exact="screening" post="for antiviral drug discovery is RNAi screens. siRNAs incorporate"/>
  <result pre="(9-d-arabinofuranosyl adenine) was the first antiviral agent licensed for systemic" exact="treatment" post="of herpes viral infections in humans (Fenner et al."/>
  <result pre="cell toxicity (Sykes 2013). It is used as a topical" exact="treatment" post="for feline herpes keratitis, albeit in vitro studies have"/>
  <result pre="to be well tolerated by cats and effective in the" exact="treatment" post="of feline keratoconjunctivitis sicca. It has also been reported"/>
  <result pre="and hepatic necrosis, and yet was not effective against FHV-1" exact="infection" post="(Nasisse et al. 1989). These findings suggest systemic administration"/>
  <result pre="systemic administration of neither acyclovir nor valacyclovir is recommended for" exact="treatment" post="of herpesvirus infections in cats. Ganciclovir, another purine nucleoside"/>
  <result pre="in animals (Sykes 2013). On the other hand, topical acyclovir" exact="treatment" post="was shown to be effective against FHV-1 conjunctivitis and"/>
  <result pre="Apart from cats, the existing studies provide data on acyclovir" exact="treatment" post="in horses, where intravenous administration resulted in 9,6-hour half-life,"/>
  <result pre="and Papich 2013). It has therefore been suggested that IV" exact="treatment" post="could be administered twice daily for equine herpesvirus-1 (EHV-1)"/>
  <result pre="equine herpesvirus-1 (EHV-1) (Riviere and Papich 2013). In birds, oral" exact="treatment" post="with 120 mg/kg of acyclovir every 12 h has"/>
  <result pre="it seems to be well tolerated and successful in the" exact="treatment" post="of FHV-1-associated conjunctivitis (Thomasy et al. 2007; Malik et"/>
  <result pre="loss. However, observed clinical symptoms withdrew within one week after" exact="treatment" post="discontinuation (Riviere and Papich 2013; Povey 1978). Interestingly, these"/>
  <result pre="In kittens experimentally infected with feline infectious peritonitis virus (FIPV)," exact="treatment" post="with neither free nor liposomal ribavirin improved survival rate"/>
  <result pre="in the mouse model, even when administered days after intracerebral" exact="infection" post="(McKinlay et al. 2014). Fig. 22.3 The chemical structure"/>
  <result pre="rifamycin-SV and its derivatives are deemed first line in the" exact="treatment" post="of intracellular pathogens and demonstrated inhibitory action in various"/>
  <result pre="a mechanism other than inhibiting DNA-dependent RNA polymerase. In vitro" exact="screening" post="for selective inhibition of RNA-dependent DNA polymerase (reverse transcriptase)"/>
  <result pre="with immunomodulatory and anti-inflammatory action and widely used for the" exact="treatment" post="of acne, rheumatoid arthritis and UTIs. Potential antiviral action"/>
  <result pre="associated with intensifying pathogenesis and organ damage in dengue virus" exact="infection" post="(Leela et al. 2016). Furthermore, the quinolones have showed"/>
  <result pre="73 has passed evaluation in Phase I trial for the" exact="treatment" post="of HCV (Butler 2008). Even though majority of natural"/>
  <result pre="been in use for over 20 years in Japan for" exact="treatment" post="of hepatitis. Its dried and processed root licorice has"/>
  <result pre="the discovery and development of anti-Ebola virus drugs for the" exact="treatment" post="of patients with Ebola virus infection. As a result,"/>
  <result pre="et al. 2014). Finally, six antibiotics which inhibit Ebola virus" exact="infection" post="(azithromycin, erythromycin, spiramycin, dirithromycin, maduramicin, clarithromycin) were selected for"/>
  <result pre="antiviral agents have been approved by FDA for Zika virus" exact="infection" post="(Cheng et al. 2016). It is important to design"/>
  <result pre="design or develop a therapeutic approach to overcome Zika virus" exact="infection" post="with a special focus on drugs targeting the virus"/>
  <result pre="such as chloroquine, azithromycin and niclosamide are used for the" exact="treatment" post="of Zika virus infection (Munjal et al. 2017). New"/>
  <result pre="and niclosamide are used for the treatment of Zika virus" exact="infection" post="(Munjal et al. 2017). New studies revealed that Alzheimer’s"/>
  <result pre="against VP2 of infectious bursal disease virus protecting against viral" exact="infection" post="in chicken (Zhang et al. 2017), porcine circovirus type"/>
  <result pre="previously disease-free countries. Hence, interferons (IFNs) have emerged as another" exact="treatment" post="agent, including IFN-α, IFN-β and IFN-γ, which are used"/>
  <result pre="Kania 2010). To conclude with, equine herpesvirus type 1 (EHV-1)" exact="infection" post="causes outbreak of respiratory and various neurological diseases in"/>
  <result pre="Also, a high-dose zidovudine/lamivudine combination was shown to protect from" exact="infection" post="when treatment was initiated before virus inoculation (Arai et"/>
  <result pre="high-dose zidovudine/lamivudine combination was shown to protect from infection when" exact="treatment" post="was initiated before virus inoculation (Arai et al. 2002)."/>
  <result pre="inhibit synthesis of DNA. They have been applied in the" exact="treatment" post="of feline herpesvirus-1 (FHV-1), significantly reducing the number of"/>
  <result pre="2 (EHV-2) by alleviating the ocular symptoms caused by the" exact="infection" post="(Collinson et al. 1994). It has also been reported"/>
  <result pre="treatment, ensuring management of new or drug-resistant viral strains, first-line" exact="treatment" post="or prophylaxis of acute infections, as well as co-infections"/>
  <result pre="inhibitors, eventually leading to interferon-free therapies for consistent clearing of" exact="infection" post="(Bryan-Marrugo et al. 2015). Perspectives for use of antiviral"/>
  <result pre="antiviral drugs in livestock animals are envisaged as the mass" exact="treatment" post="for the control of the disease (on a large"/>
  <result pre="the control of the disease (on a large scale), whereas" exact="treatment" post="in companion animals favours an individual approach. The main"/>
  <result pre="veterinary antiviral chemotherapy is a better understanding of the viral" exact="infection" post="pathogenesis as well as development of sophisticated means for"/>
  <result pre="a single method is preferred, while for large-scale livestock, mass" exact="treatment" post="therapy is used; that is why antiviral drugs and"/>
  <result pre="activityRuss J Gen Chem201585102441244810.1134/S1070363215100394 AraiMEarlDDYamamotoJKIs AZT/3TC therapy effective against FIV" exact="infection" post="or immunopathogenesis?Vet Immunol Immunopathol2002853–418920410.1016/S0165-2427(01)00426-311943320 AyisiNet al.Combination chemotherapy: interaction of"/>
  <result pre="in conjunctival and white blood cellsAm J Vet Res20066761025103210.2460/ajvr.67.6.102516740097 BrodinPChristopheTHigh-content" exact="screening" post="in infectious diseasesCurr Opin Chem Biol201115453453910.1016/j.cbpa.2011.05.02321684803 Bryan-MarrugoOet al.History and"/>
  <result pre="Exp Ther198121923093157288622 DebRet al.Monoclonal antibody and its use in the" exact="diagnosis" post="of livestock diseasesAdv Biosci Biotechnol20134045010.4236/abb.2013.44A008 DemainALImportance of microbial natural"/>
  <result pre="Chem19984181252126210.1021/jm970559i9548815 PoveyREffect of orally administered ribavirin on experimental feline calicivirus" exact="infection" post="in catsAm J Vet Res197839813371341697143 Prichard MN (2007) New"/>
  <result pre="mononuclear cellsAm J Vet Res201475327328110.2460/ajvr.75.3.27324564313 ShaharyarMet al.Synthesis, characterization and pharmacological" exact="screening" post="of novel benzimidazole derivativesArab J Chem20169Supplement 1S342S34710.1016/j.arabjc.2011.04.013 ShawTet al.In"/>
  <result pre="B virusAntimicrob Agents Chemother199438471972310.1128/AAC.38.4.7198031035 ShipkowitzNet al.Suppression of herpes simplex virus" exact="infection" post="by phosphonoacetic acidAppl Microbiol19732632642674356456 SiebeckNet al.Effects of human recombinant"/>
  <result pre="sarcoma virus production by rifamycin derivativeJ Virol197618244545358073 SzymańskiPMarkowiczMMikiciuk-OlasikEAdaptation of high-throughput" exact="screening" post="in drug discovery—toxicological screening testsInt J Mol Sci201213142745210.3390/ijms1301042722312262 TanS-Let"/>
  <result pre="rifamycin derivativeJ Virol197618244545358073 SzymańskiPMarkowiczMMikiciuk-OlasikEAdaptation of high-throughput screening in drug discovery—toxicological" exact="screening" post="testsInt J Mol Sci201213142745210.3390/ijms1301042722312262 TanS-Let al.Hepatitis C therapeutics: current"/>
  <result pre="Rev Drug Discov2002186710.1038/nrd93712415247 TeHSRandallGJensenDMMechanism of action of ribavirin in the" exact="treatment" post="of chronic hepatitis CGastroenterol Hepatol200733218 ThiryEet al.Feline herpesvirus infection."/>
  <result pre="of Certain 2, 5, 6-Trihalo-1-(. beta.-D-ribofuranosyl) benzimidazolesJ Med Chem199538204098410510.1021/jm00020a0257562945 VallerMJGreenDDiversity" exact="screening" post="versus focussed screening in drug discoveryDrug Discov Today20005728629310.1016/S1359-6446(00)01517-810856911 VeljkovicVet"/>
  <result pre="5, 6-Trihalo-1-(. beta.-D-ribofuranosyl) benzimidazolesJ Med Chem199538204098410510.1021/jm00020a0257562945 VallerMJGreenDDiversity screening versus focussed" exact="screening" post="in drug discoveryDrug Discov Today20005728629310.1016/S1359-6446(00)01517-810856911 VeljkovicVet al.Virtual screen for"/>
 </snippets>
</snippetsTree>
